Abstract
CONTEXT: The endocannabinoid system (ECS) is a signaling system composed of endocannabinoids (eCBs), their receptors, and the enzymes involved in their synthesis and metabolism. Alterations in the ECS are linked to the development of cardiometabolic diseases. OBJECTIVE: Here, we investigated the relationship between plasma levels of eCBs and their analogues with body composition and cardiometabolic risk factors. METHODS: The study included 133 young adults (age 22.1 ± 2.2 years, 67% women). Fasting plasma levels of eCBs and their analogues were measured using liquid chromatography-tandem mass spectrometry. Body composition, brown adipose tissue (BAT) volume, glucose uptake, and traditional cardiometabolic risk factors were measured. RESULTS: Plasma levels of eCBs and several eCB analogues were positively correlated with adiposity and traditional cardiometabolic risk factors (eg, serum insulin and triacylglyceride levels, all r ≥ 0.17 and P ≤ .045). Plasma levels of 2-arachidonoyl glycerol and N-pentadecenoylethanolamine were negatively correlated with BAT volume and glucose uptake (all r ≤ -0.17 and P ≤ .047). We observed that the plasma levels of eCBs and their analogues were higher in metabolically unhealthy overweight-obese participants than in metabolically healthy overweight-obese participants. CONCLUSION: Our findings show that the plasma levels of eCBs and their analogues are related to higher levels of adiposity and worse cardiometabolic profile.
Original language | English |
---|---|
Pages (from-to) | 1351-1360 |
Number of pages | 10 |
Journal | The Journal of clinical endocrinology and metabolism |
Volume | 109 |
Issue number | 5 |
Early online date | 15 Nov 2023 |
DOIs | |
Publication status | Published - May 2024 |
Bibliographical note
Publisher Copyright:© The Author(s) 2023. Published by Oxford University Press on behalf of the Endocrine Society.
Funding
This study was supported by the Spanish Ministry of Economy and Competitiveness via the Fondo de Investigaci\u00F3n Sanitaria del Instituto de Salud Carlos III (PI13/01393) and PTA-12264, Retos de la Sociedad (DEP2016-79512-R) and European Regional Development Fund (ERDF), the Spanish Ministry of Education (FPU16/02828, FPU17/01523 and FPU19/01609), the Fundaci\u00F3n Iberoamericana de Nutrici\u00F3n (FINUT), the Redes Tem\u00E1ticas de Investigaci\u00F3n Cooperativa RETIC (Red SAMID RD16/0022), the AstraZeneca HealthCare Foundation, the University of Granada Plan Propio de Investigaci\u00F3n 2016 -Excellence actions: Unit of Excellence on Exercise and Health (UCEES), the Junta de Andaluc\u00EDa, Consejer\u00EDa de Conocimiento, Investigaci\u00F3n y Universidades (ERDF; ref. SOMM17/6107/UGR and DOC 01151), the Fundaci\u00F3n Alfonso Martin Escudero, the Netherlands CardioVascular Research Initiative: the Dutch Heart Foundation, Dutch Federation of University Medical Centers, the Netherlands Organization for Health Research and Development and the Royal Netherlands Academy of Arts and Sciences (CVON2017-20 GENIUS-2) to P.C.N.R., and the China Scholarship Council (no. 201707060012) to X.D.
Funders | Funder number |
---|---|
Dutch Federation of University Medical Centers | |
AstraZeneca HealthCare Foundation | |
Ministerio de Economía y Competitividad | |
Fundación Alfonso Martín Escudero | |
Hartstichting | |
ZonMw | |
University of Granada Plan Propio de Investigación | |
European Regional Development Fund | |
Ministerio de Educación, Cultura y Deporte | FPU16/02828, FPU17/01523, FPU19/01609 |
China Scholarship Council | 201707060012 |
Fundación Iberoamericana de Nutrición | RD16/0022 |
Consejería de Conocimiento, Investigación y Universidad, Junta de Andalucía | SOMM17/6107/UGR, DOC 01151 |
Koninklijke Nederlandse Akademie van Wetenschappen | CVON2017-20 GENIUS-2 |
Instituto de Salud Carlos III | PTA-12264, PI13/01393, DEP2016-79512-R |
Keywords
- 2-arachidonoyl glycerol
- anandamide
- body composition
- cardiometabolic risk factors
- endocannabinoid system
- visceral adipose tissue